Skip to main
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics Inc. shows a robust financial outlook driven by the promising clinical results of its lead product, Veligrotug, which exhibits best-in-class potential for treating thyroid eye disease through significant reduction in proptosis and improved quality of life for patients. The anticipated market expansion from Veligrotug and the addition of VRDN-003, a subcutaneous delivery option, are expected to enhance the company’s competitive position and market share in this therapeutic area. Furthermore, successful clinical execution has been reflected in the stock's strong year-to-date gains and an increased target valuation, indicating a high probability of continued success and investor confidence in the company's growth trajectory.

Bears say

Viridian Therapeutics faces significant downside risks primarily due to potential delays in the launch of its lead product candidate, Veligrotug, which could adversely affect valuations. The prospect of negative outcomes from the ongoing REVEAL studies could further exacerbate the company's financial position, potentially leading to a substantial decrease in share value if VRDN-003 is removed from projections. Additionally, competitive pressures from well-capitalized rivals with established market presence and concerns regarding intellectual property protection could considerably impair Viridian's market share and pricing strategy.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.